BRPI0810197A2 - Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetra-hidroxibutil)-1h-imidazo l-2-il)etanona oxima - Google Patents

Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetra-hidroxibutil)-1h-imidazo l-2-il)etanona oxima

Info

Publication number
BRPI0810197A2
BRPI0810197A2 BRPI0810197-3A2A BRPI0810197A BRPI0810197A2 BR PI0810197 A2 BRPI0810197 A2 BR PI0810197A2 BR PI0810197 A BRPI0810197 A BR PI0810197A BR PI0810197 A2 BRPI0810197 A2 BR PI0810197A2
Authority
BR
Brazil
Prior art keywords
tetrahydroxibutil
oxima
ethanone
imidazo
solid forms
Prior art date
Application number
BRPI0810197-3A2A
Other languages
English (en)
Inventor
Wenxue Wu
Haiming Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of BRPI0810197A2 publication Critical patent/BRPI0810197A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0810197-3A2A 2007-04-12 2008-04-11 Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetra-hidroxibutil)-1h-imidazo l-2-il)etanona oxima BRPI0810197A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92303707P 2007-04-12 2007-04-12
PCT/US2008/060036 WO2008128045A1 (en) 2007-04-12 2008-04-11 Solid forms of (e) -1- (4- ( (ir, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl) ethanone oxime

Publications (1)

Publication Number Publication Date
BRPI0810197A2 true BRPI0810197A2 (pt) 2014-12-30

Family

ID=39639233

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810197-3A2A BRPI0810197A2 (pt) 2007-04-12 2008-04-11 Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetra-hidroxibutil)-1h-imidazo l-2-il)etanona oxima

Country Status (23)

Country Link
US (2) US20080275099A1 (pt)
EP (1) EP2139865B1 (pt)
JP (1) JP5496080B2 (pt)
KR (1) KR20100015464A (pt)
CN (1) CN101284818B (pt)
AR (1) AR065979A1 (pt)
AU (1) AU2008240255B2 (pt)
BR (1) BRPI0810197A2 (pt)
CA (1) CA2683963A1 (pt)
CL (1) CL2008001043A1 (pt)
CO (1) CO6230981A2 (pt)
EA (1) EA017042B1 (pt)
EC (1) ECSP099681A (pt)
ES (1) ES2453543T3 (pt)
HK (1) HK1124851A1 (pt)
IL (1) IL201037A (pt)
MX (1) MX2009010904A (pt)
NZ (1) NZ579689A (pt)
PE (1) PE20090072A1 (pt)
TW (1) TWI412362B (pt)
UY (1) UY31012A1 (pt)
WO (1) WO2008128045A1 (pt)
ZA (1) ZA200906493B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
AR065980A1 (es) 2007-04-12 2009-07-15 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en imidazol
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
AU2009271408A1 (en) * 2008-06-18 2010-01-21 Lexicon Pharmaceuticals, Inc. Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl) -1H-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
EP2537831B1 (en) 2010-02-18 2014-12-03 Daiichi Sankyo Company, Limited Imidazole derivative
JP5757635B2 (ja) 2010-06-28 2015-07-29 第一三共株式会社 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
US9120835B2 (en) 2011-06-28 2015-09-01 Daiichi Sankyo Company Limited Phosphoric acid ester derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567194A (en) 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
ZA974811B (en) * 1996-05-31 1997-12-30 Univ Wollongong Novel therapeutic compounds.
UA94737C2 (ru) * 2006-02-24 2011-06-10 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазола, композиция, которая их содержит, и их применение
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
AR065980A1 (es) * 2007-04-12 2009-07-15 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en imidazol

Also Published As

Publication number Publication date
US20080275099A1 (en) 2008-11-06
JP5496080B2 (ja) 2014-05-21
KR20100015464A (ko) 2010-02-12
EP2139865A1 (en) 2010-01-06
AU2008240255B2 (en) 2013-07-04
CO6230981A2 (es) 2010-12-20
EA200970940A1 (ru) 2010-02-26
AU2008240255A1 (en) 2008-10-23
WO2008128045A8 (en) 2010-01-21
CN101284818B (zh) 2012-10-03
CA2683963A1 (en) 2008-10-23
WO2008128045A1 (en) 2008-10-23
NZ579689A (en) 2011-10-28
HK1124851A1 (pt) 2009-07-24
TW200848027A (en) 2008-12-16
MX2009010904A (es) 2009-10-26
US8658682B2 (en) 2014-02-25
IL201037A (en) 2015-08-31
TWI412362B (zh) 2013-10-21
PE20090072A1 (es) 2009-02-18
US20090298901A1 (en) 2009-12-03
CN101284818A (zh) 2008-10-15
AR065979A1 (es) 2009-07-15
IL201037A0 (en) 2010-05-17
ECSP099681A (es) 2009-12-28
CL2008001043A1 (es) 2008-09-26
ZA200906493B (en) 2010-11-24
EA017042B1 (ru) 2012-09-28
ES2453543T3 (es) 2014-04-08
JP2010523707A (ja) 2010-07-15
UY31012A1 (es) 2008-09-02
EP2139865B1 (en) 2014-01-01

Similar Documents

Publication Publication Date Title
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
BRPI0810197A2 (pt) Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetra-hidroxibutil)-1h-imidazo l-2-il)etanona oxima
CY2013047I2 (el) Ενωσεις διαρυλυδαντοϊνης
BRPI0920598A2 (pt) formas sólidas de n-(4(7-azabiciclo[2.2.1]heptan-7-il)-2-(triflúor-metil)fenil)-4-oxo-5-(triflúor-metil)-1,4-di-hidroquinolina-3-carboxamida
NL1031385A1 (nl) Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK3056214T3 (da) Hidtil ukendte adjuvanssammensætninger
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
DK1979356T3 (da) Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
BRPI0918433A2 (pt) combinação herbicida compreendendo difluormetano sulfonilanildas substittuídas por demetoxitriazinila.
ATE479676T1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
DE502006000770D1 (de) Konservierungsmittel
DE602006019852D1 (de) Verriegelungsspannfutter
NL1031335A1 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
DE112005003586A5 (de) Bohrfutter
BRPI0923048A2 (pt) "composto de aminopirazol".
DE502006001027D1 (de) Cyanuraten
BRPI0915099A2 (pt) Antioxidante altamente eficaz à base de trealulose.
BRPI0814748A2 (pt) Compostos de alditóis substituídos, composições e métodos
ATE435865T1 (de) Als pde5-inhibitoren verwendete pyrazoloä4,3- düpyrimidin-5-ylderivate
DE502006003183D1 (de) Axialkolbenverdichter
BRPI0914167A2 (pt) formas sólidas de (1r,2s,3r)-1-(2-(isoxa-zol-3-il)-1h-imidazol-4il) butano-1,2,3,4-tetraol e métodos de uso das mesmas
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
ITMI20050051A1 (it) Fotodiodio organico di poli-9,9-diottil-fluorene
DK2097400T3 (da) Kondenseret, substitueret aminopyrrolidinderivat

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.